A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole

• Status: Completed
• Trial end date: 2008-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effect of an adrenocorticoid antagonist (ketoconazole), 600 mg per day for 4 weeks, in the treatment of patients with central serous chorioretinopathy (CSC).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Manhattan Eye, Ear & Throat Hospital
• Collaborator: LuEsther T. Mertz Retinal Research Center
• Treatments: Ketoconazole

Criteria

Inclusion Criteria:

1. Age less than 60 years

2. Must have clinical signs of CSC with leakage from the level of the RPE during fluorescein angiography and neurosensory detachment documented by optical coherence tomography (OCT).

3. Be able to return for all study visits for 3 months' duration.

4. Be able to provide written informed consent

5. Must have sufficiently clear media to allow for adequate fundus photography

Exclusion Criteria:

1. Have choroidal neovascularization.

2. Have any evidence of clinically significant intraocular inflammation, angioid streaks, presumed ocular histoplasmosis syndrome, or other precursor of choroidal neovascularization.

3. Have additional eye disease that compromises the visual acuity of the study eye.

4. Are receiving any systemic steroid therapy

5. Have any significant medical history

6. Have a history of severe hypersensitivity reaction to any of the dyes or the drug used in the study.

7. Have any history of ocular conditions that may mimic CSC

8. Are pregnant